Creatine for Depression Shows Mixed Early Results

Key Takeaways

• This was a review of five existing randomized, double-blind, placebo-controlled trials, not a new clinical trial.
• Roughly 240 participants were included, with results too mixed and study designs too different for a pooled conclusion.
• Two studies found benefit when 5 g/day of creatine was added to escitalopram, and one found benefit alongside cognitive behavioural therapy.
• Other trials found no measurable benefit, including in treatment-resistant depression and in adolescent girls with major depressive disorder.
• In women with bipolar depression, creatine did not help and was linked to hypomania or mania in two participants.
• For now, creatine remains a well-studied sports supplement, not an evidence-based depression treatment.

What the new review actually found

The new paper from University of Ottawa researchers asks a fair question: could creatine have a role in depression treatment, not just in sport and exercise nutrition? The short answer is possibly, but the evidence is early and inconsistent.

Rather than running a new experiment, the authors reviewed the small pool of randomized, double-blind, placebo-controlled trials already published. They identified five trials reported across six papers, covering roughly 240 participants split about evenly between creatine and placebo. Four studies involved major depressive disorder, while one involved bipolar disorder during a major depressive episode.

The main signal was narrow. In two studies, participants taking 5 grams of creatine daily alongside the antidepressant escitalopram improved significantly more than placebo groups with major depressive disorder. Another trial found a greater reduction in symptoms when creatine was paired with cognitive behavioural therapy.

But that was not the whole picture. Other studies found no measurable benefit, including trials in people who had not responded to previous antidepressants and in adolescent girls with major depressive disorder. Most importantly, the bipolar study found no benefit and reported hypomania or mania in two participants.

That makes this a story about a signal worth studying, not a breakthrough. If you use creatine for performance, strength, or lean mass, this review does not change what creatine is best supported for. If you are wondering whether creatine can treat depression, the answer today is still no: it is not a proven depression treatment.

How the evidence was built and why that matters

The design of this paper matters because reviews can sound stronger than the underlying evidence. Here, the researchers did not conduct a new intervention trial. They re-examined the existing randomized placebo-controlled literature and chose to summarize studies individually instead of pooling them into a meta-analysis.

That was a sensible choice. The trials differed in important ways:

• Population: adults with major depressive disorder, adolescent girls with major depressive disorder, and women with bipolar depression.
• Background treatment: some studies added creatine to escitalopram, one paired it with cognitive behavioural therapy, and others involved different clinical contexts.
• Response history: one study included patients who had not responded to previous antidepressants.
• Geography and demographics: participants came from South Korea, the United States, Brazil, India and Israel, and most were women.

Those differences make it hard to claim that “creatine works for depression” in any broad sense. The study pool was also small, both in number of trials and total participants. Small trials are more vulnerable to chance findings, publication bias, and exaggerated effects.

Just as importantly, this review was looking at adjunctive use in several of the positive studies. In plain language, creatine was not replacing standard care; it was being tested alongside treatment such as escitalopram or therapy. That distinction matters for readers and for clinicians.

For background on what creatine is firmly supported for, our creatine guides cover the evidence base in sport, body composition, and everyday supplementation.

Why creatine is even being studied for mood

The theory behind this line of research is not random. Creatine helps regenerate adenosine triphosphate, or ATP, the molecule cells use to transfer energy. That matters because the brain is metabolically expensive tissue: even at rest, it needs a constant, reliable energy supply.

The review notes that lower brain energy production has been linked with depression, and that creatine may influence some overlapping pathways with antidepressants. That creates a plausible biological hypothesis: if some forms of depression involve impaired brain energy metabolism, perhaps improving that energy buffering system could help symptoms in some people.

Still, a plausible mechanism is not the same thing as clinical proof. Plenty of ideas in nutrition and psychiatry make sense on paper but do not translate into meaningful real-world benefits. That is why randomized trials matter more than mechanism alone.

Creatine also has a practical advantage as a research candidate: it is inexpensive, widely available, and already heavily studied in sport nutrition. The best-supported form remains creatine monohydrate. Position stands and reviews such as Kreider et al. (2017), ISSN Position Stand: Safety and Efficacy of Creatine — JISSN and Antonio et al. (2021), Common questions and misconceptions about creatine supplementation — JISSN consistently identify monohydrate as the most studied form for efficacy and safety in healthy populations.

That broader safety-and-efficacy literature is useful context, but it does not automatically transfer to psychiatric treatment. A supplement can be well studied for muscle and performance yet still remain unproven, or inappropriate, for a mental-health indication.

What this means in practice for creatine users

For most readers, the practical takeaway is straightforward: do not self-treat depression with creatine. If you have depression symptoms, talk to a physician, nurse practitioner, psychologist, psychiatrist, or other qualified clinician. In Canada, that means using the supplement conversation as part of care, not instead of care.

The positive studies in this review were not testing a typical gym use case like “take creatine and see if your mood improves.” They mainly looked at creatine as an adjunct to treatment, and the dose highlighted in the positive escitalopram studies was 5 g/day. That is within the familiar maintenance range many people already use for training.

If you are taking creatine for strength, sprint performance, or lean mass, there is no reason to change a routine that already fits mainstream guidance. For general supplementation, monohydrate remains the standard, with many users taking around 3 to 5 g/day, and some choosing a loading phase of about 20 g/day split into 4 doses for 5 to 7 days before moving to maintenance. If you need help estimating intake, our creatine dosage calculator can help, and our best creatine rankings and creatine brand reviews cover product quality and formulation basics.

But none of that should be confused with depression treatment. The supplement practices used for performance goals are not evidence that creatine can manage a mood disorder.

The bipolar safety caution is the most important clinical note

The clearest safety message from this review concerns bipolar disorder. In the one bipolar depression study included, creatine did not help and was associated with hypomania or mania in two participants.

That does not prove creatine causes mania in everyone with bipolar disorder, or even in most people with bipolar disorder. The trial was small, and the entire evidence base here is limited. But it is a clinically meaningful warning sign, especially because bipolar illness can be destabilized by treatments that appear activating in some individuals.

For that reason, anyone with bipolar disorder should be especially cautious about creatine use for mood-related reasons and should discuss it with a clinician who knows their diagnosis, medication history, and current symptom pattern. The same goes for anyone with a history of mania, hypomania, mixed episodes, or rapid mood shifts.

This is a good example of why supplement safety is context dependent. In healthy athletes, creatine monohydrate is widely regarded as one of the better-supported sports supplements. But in a psychiatric setting, the relevant question is not just general tolerability. It is whether the intervention might alter symptoms, interact with treatment plans, or complicate diagnosis and monitoring.

If you are shopping for a standard monohydrate product for training purposes, our creatine product catalog explains common product formats. If you are considering creatine because of depression or bipolar symptoms, product selection is not the main issue. Clinical oversight is.

Where this fits in the bigger creatine evidence base

Creatine’s reputation was built on exercise science, not psychiatry. The strongest evidence remains in areas such as high-intensity performance, strength, training adaptations, and support for increasing intramuscular creatine stores. That is why monohydrate is still the default recommendation in evidence-based supplementation guides.

This depression review sits in a newer, more exploratory branch of the literature. It is interesting because it points to a biologically plausible and clinically important question. Depression is common, current treatments do not help everyone, and adjunctive strategies are worth studying. But “worth studying” is very different from “ready for practice.”

A fair reading of the paper is:

• Encouraging enough to justify larger, better-designed trials.
• Too inconsistent to support routine use for depression.
• Potentially more relevant in certain subgroups or treatment contexts than others.
• Not reassuring enough to ignore the bipolar signal.

That nuance matters in health reporting. Supplements often get framed as miracle aids or total duds. The evidence here supports neither extreme. Instead, it suggests a small body of mixed clinical data, a plausible mechanism, and a clear need for larger replication.

Readers who want a broader overview of established creatine science can also consult Examine.com — Creatine evidence summary, though when it comes to depression specifically, this new review still describes a field in its infancy.

Bottom line for Canadian readers

The bottom line is simple: creatine is not a proven treatment for depression. This new review found a mixed pattern across five small randomized trials, with some benefit in a few major depressive disorder studies and no benefit in others. In bipolar depression, the findings were not just negative but cautionary.

For Canadians already taking creatine for training, this paper does not overturn mainstream guidance on sports use. Creatine monohydrate remains the best-studied form, and typical maintenance intakes are still in the familiar 3 to 5 gram range for healthy users. But this review should not be read as a reason to start creatine specifically for depression without medical advice.

If you have depression symptoms, speak to a qualified clinician. If you have bipolar disorder or any history of mania or hypomania, speak to a clinician before using creatine for any mood-related purpose. And if you are already under treatment, do not stop or swap prescribed care for a supplement based on early-stage evidence.

The most accurate headline on the science today is not “creatine treats depression.” It is this: creatine is being studied for depression, the early data are mixed, and more rigorous research is needed before practice should change.

Creatine and depression: what this review showed

• 5 randomized placebo-controlled trials reviewed — Reported across six papers
• ~240 total participants — Roughly split evenly between creatine and placebo
• 5 g/day dose used in the positive escitalopram studies — In major depressive disorder
• 2 bipolar participants with hypomania or mania — Important safety caution from one trial

Frequently Asked Questions

Sources & Further Reading

• Kreider et al. (2017), ISSN Position Stand: Safety and Efficacy of Creatine — JISSN
• Antonio et al. (2021), Common questions and misconceptions about creatine supplementation — JISSN
• Examine.com — Creatine evidence summary